Talazoparib Tosylate Patent Expiration

Talazoparib Tosylate is used for treating advanced breast cancer and metastatic prostate cancer with specific gene mutations. It was first introduced by Pfizer Inc in its drug Talzenna on Oct 16, 2018.


Talazoparib Tosylate Patents

Given below is the list of patents protecting Talazoparib Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Talzenna US10189837 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt Oct 20, 2031 Pfizer
Talzenna US10780088 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Jul 27, 2029 Pfizer
Talzenna US8012976 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Oct 19, 2029 Pfizer
Talzenna US8420650 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Jul 27, 2029 Pfizer
Talzenna US8735392 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt Oct 20, 2031 Pfizer
Talzenna US9820985 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Jul 27, 2029 Pfizer


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳